Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate CancerGenital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorderRecruitingPhase 12026-07-02NCT07140900

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Amgen180

16 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Cabrini HospitalClaytonAustralia1
Calvary Mater Newcastle HospitalWaratahAustralia13
Centre Hospitalier Universitaire VaudoisLausanneSwitzerland19
Chris Obrien LifehouseCamperdownAustralia17
Cleveland Clinic FoundationClevelandUnited States370
Dana Farber Cancer InstituteBostonUnited States300
Kantonsspital GraubuendenChurSwitzerland11
Kantonsspital Sankt GallenSankt GallenSwitzerland14
Peter MacCallum Cancer CentreMelbourneAustralia149
Sarah Cannon Research InstituteNashvilleUnited States119
South Texas Accelerated Research Therapeutics - CarolinasMyrtle BeachUnited States2
The Alfred HospitalMelbourneAustralia110
Thomas Jefferson UniversityPhiladelphiaUnited States165
University of California San FranciscoSan FranciscoUnited States80
University of MinnesotaMinneapolisUnited States325
University of Pittsburgh Medical Center Hillman Cancer CenterPittsburghUnited States4